Erythropoietin-stimulating agents in the management of anemia of end-stage renal disease patients on regular hemodialysis: A prospective randomized comparative study from Qatar

Hemodialysis International

Volumn 19, Issue 1, 2015, Pages 33-43

  Al Ali, Fadwa Saqr ^a   El Sayed Abdelfattah, Mohamed ^a   Fawzy, Ashraf Ahmed ^a   Hamdy, Ahmed Farouk ^a   Abdulla, Aisha Elsayed ^a  

^a HAMAD GENERAL HOSPITAL   (Qatar)

Author keywords

Anemia; Comparison; Erythropoietin stimulating agents; Hemodialysis

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE CORONARY SYNDROME; ADULT; ANEMIA; ARTICLE; BACTEREMIA; BLEEDING; BRAIN HEMORRHAGE; CHEST INFECTION; COLLAPSE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; EPIGASTRIC PAIN; FEMALE; FEMUR FRACTURE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERVOLEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; PERIANAL ABSCESS; QATAR; RANDOMIZED CONTROLLED TRIAL; SUBDURAL HEMATOMA; SUPERIOR CAVA VEIN OBSTRUCTION; VAGINA BLEEDING; COMPLICATION; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

ANEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QATAR; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84920943465     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12181     Document Type: Article

References (26)

1. McClellan W, Aronoff SL, Bolton WK. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004; 20:1501-1510.
2. Barany P, Petterson E, Konarski-Svensson JK. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant. 1993; 8:426-432.
3. Perlman RL, Finkelstein FO, Liu L, etal. Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the renal research institute-CKD study. Am J Kidney Dis. 2005; 45:658-666.
4. Locatelli F, Aljama P, Barany P, etal.; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19(Suppl 2):ii1-ii47.
5. Pisoni RL, Bragg-Gresham JL, Young EW, etal. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44:94-111.
6. Collins AJ, Brenner RM, Ofman JJ, etal. Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005; 46:481-488.
7. Agarwal AK, Silver MR, Reed JE, etal. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med. 2006; 260:577-585.
8. Provenzano R, Besarab A, Macdougall IC, etal.; BA16528 Study Investigators. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: Results of a phase II study. Clin Nephrol. 2007; 67:306-317.
9. Li WY, Chu TS, Huang JW, Wu MS, Wu KD. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. J Formos Med Assoc. 2008; 107:843-850.
10. Vanrenterghem Y, Bárány P, Mann JF, etal. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002; 62:2167-2175.
11. Levin NW, Fishbane S, Cañedo FV, etal. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomized non-inferiority trial (MAXIMA). Lancet. 2007; 370:1415-1421.
12. Sulowicz W, Locatelli F, Ryckelynck JP, etal.; PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007; 2:637-646.
13. Carrera F, Lok CE, de Francisco A, etal.; PATRONUS Investigators. Maintenance treatment of renal anemia in hemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: A randomized comparative trial. Nephrol Dial Transplant. 2010; 25:4009-4017.
14. Fleiss JL. Statistical methods for rates and proportion. 2nd ed. John Wiley & Sons, NY, 1981; Chapter 3.
15. van der Putten K, van der Baan FH, Schellekens H, Gaillard CA. Hemoglobin variability in patients with chronic kidney disease in the Netherlands. Int J Artif Organs. 2009; 32:787-793.
16. Portolés J, López-Gómez JM, Aljama P. A prospective multicenter study of the role of anemia as a risk factor in hemodialysis patients: The MAR Study. Nephrol Dial Transplant. 2007; 22:500-507.
17. Yang W, Israni RK, Brunelli SM, etal. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007; 18:3164-3170.
18. Clinical KDIGO. Practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2:279-335.
19. Locatelli F, Vecchio LD. Erythropoiesis-stimulating agents in renal medicine. Oncologist. 2011; 16:19-24.
20. Mann JF, de Francisco A, Nassar G, Canaud B. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol. 2011; 76:9-15.
21. Mallick S, Rafiroiu A, Kanthety R, Iqbal S, Malik R, Rahman M. Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Blood Purif. 2012; 33:238-244.
22. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004; 44:866-876.
23. Zhang Y, Thamer M, Cotter D, Kaufman J, Hernan MA. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2009; 4:638-644.
24. Ifudu O, Uribarri J, Rajwani I, etal. Gender modulates responsiveness to recombinant erythropoietin. Am J Kidney Dis. 2001; 38:518-522.
25. Deiss A. Iron metabolism in reticuloendothelial cells. Semin Hematol. 1983; 20:81-90.
26. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990; 322:1689-1692.